In the News
India price advantage helped Boost Business
NDTV- 22/11/2015. Peter Bains, director and CEO at Syngene International, told NDTV that it witnessed strong growth across its business verticals in the second quarter, which was supported by significant cost advantage in India.
ET-NOW - 03/10/2015. An exclusive interview with Kiran Mazumdar Shaw, Peter Bains and Manoj Nerurkar on Syngene's operations and journey so far at the sprawling Syngene campus.
Syngene eyes capacity and capability expansion post-IPO
Outsourcing Pharma-21/10/2015. Syngene says it will invest in new capacity and capabilities, including a viral testing facility, as it reports strong results in its first quarter post-IPO.
Syngene Q2 net profit rises 31% to Rs 52 crore
Economic Times- 20/10/2015 .Syngene International, research arm of Biocon, today posted 30.69 per cent rise in its net profit at Rs 52.29 crore for the second quarter ended September 30 .
Syngene share strength reflects India's contract research opportunity
Times of India-15/09/2015 .Among the major India players, Syngene is the only pure CRO, and is estimated to have 40% of the market.
Syngene International Jumps 32% From Issue Price Within One Quarter
CNBC TV18- 15/09/2015. "Syngene International is targeting a growth of USD 250 million by FY2018", says Peter Bains CEO of the company) .
CROs Are Making Headlines -India’s drug discovery service sector is heating up
Contract Pharma-11/09/2015 .Syngene says it is intent on establishing new capabilities and augmenting existing services across the discovery & development continuum..
Syngene to spend $100 m on new plant at Mangalore SEZ
Financial Express-29/08/2015 .Syngene is planning to set up a multi-product, multi-client contract manufacturing facility at Mangalore special economic zone (MSEZ) at an investment of $100 million (around Rs 660 crore).
Syngene International makes stellar debut, ends day up 24% over issue price
Economic Times-11/08/2015 .It hit an intraday high of Rs 318.20 over its issue price, before settling the day at Rs 310.40,up 24.16 per cent on the BSE.
Syngene International, India’s first contract research organisation is all set to go for an IPO
Business India - 23/06/2015 .Syngene International, India’s first contract research organisation is all set to go for an IPO.